Hologic Inc

HOLX remains in a Stage 2 advance with higher highs and higher lows, reinforced by a bullish EMA alignment and strong momentum. However, price is extended to fresh highs and RSI is in extreme overbought territory, making immediate entry inadvisable. Medium- and long-term biases remain bullish, so defer engagement and await a shallow pullback into the rising EMA 20–50 area or a brief consolidation near recent support before participating in the next leg higher.

• ↑Q3 2025 revenue of $1.024B (+0.4% YoY) beat guidance by $14M
• ↑Launching Genius AI Detection Pro and Envision relaunch to improve imaging diagnostics
• ↓China sales dropped >50%, reducing Q3 revenue by ~$10M